Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of TYRA-300 in Adults with Low Grade Upper Tract Urothelial Carcinoma to Assess Efficacy and Safety

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria France Spain
  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    Spain
  • A study of SKB410, enfortumab vedotin, and pembrolizumab combination for patients with locally advanced or metastatic urothelial cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France The Netherlands Spain
  • A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

    Recruiting

    2 1 1
    Germany Spain
  • Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

    Recruiting

    4 1 1 1
    Investigated Diseases:
    Austria Belgium Czechia Denmark France Germany +5
  • Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

    Recruiting

    2 1 1
    Denmark France Italy Spain
  • Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

    Recruiting

    1 1 1
    Investigated Drugs:
    Belgium France Germany Ireland Italy The Netherlands +3
  • Study on PET Imaging with Fianlimab and Cemiplimab for Patients with Advanced Solid Tumors, with or without Platinum-Based Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    The Netherlands
  • Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Italy
  • Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1 1
    Austria Belgium France Germany Italy Poland +1